{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:58:10Z","timestamp":1790679490882,"version":"4.1.0"},"reference-count":44,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2026,7,19]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current clinical approaches to inherited prostate cancer (PCa) risk rely on binary classification of pathogenic variant (PV) carrier status without accounting for gene-specific heterogeneity or polygenic risk. We developed an integrated genetic risk model reflecting a continuum of inherited susceptibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the UK Biobank (UKB; n=218\u2009484), we evaluated associations of PVs in 11 clinically recommended genes and a polygenic risk score (PRS) with incident PCa using Cox models. A continuum model (GenProb-PCa) incorporating gene-specific PVs and PRS was developed and compared with binary PV-based models. Model performance was assessed using discrimination, calibration and continuous net reclassification index (cNRI). External validation was performed in a health system cohort, the Genomic Health Initiative (GHI; n=6590).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five genes (\n                      <jats:italic>ATM<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA2<\/jats:italic>\n                      ,\n                      <jats:italic>CHEK2<\/jats:italic>\n                      ,\n                      <jats:italic>HOXB13<\/jats:italic>\n                      ,\n                      <jats:italic>MSH2<\/jats:italic>\n                      ) and the PRS were independently associated with PCa risk (all p&lt;0.001) in UKB. Compared with binary models, GenProb-PCa demonstrated superior discrimination (C-index 0.69 vs 0.52; p&lt;0.001), with significant improvement in reclassification (cNRI 0.58; p&lt;0.001). Findings were validated in GHI using the UKB-derived coefficients (C-index 0.64 vs 0.54, p&lt;0.001; cNRI 0.31, p&lt;0.001). Compared with binary PV-based models, 20% of non-PV carriers were reclassified to higher risk groups and 60% of carriers to lower risk groups. The model identified individuals at markedly elevated lifetime risk, with cumulative incidence exceeding 20% by age 75 among the top 8% of the distribution.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An integrated continuum genetic risk model, GenProb-PCa, improves PCa risk stratification beyond binary approaches by capturing heterogeneity in inherited risk. This framework may enable more precise risk-based screening strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jmg-2026-111746","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:20:18Z","timestamp":1785345618000},"page":"676-682","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Unified genetic risk score for prostate cancer enables improved risk stratification for clinical decision-making"],"prefix":"10.1136","volume":"63","author":[{"given":"Zhuqing","family":"Shi","sequence":"first","affiliation":[{"name":"Program for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley J","family":"Mulford","sequence":"additional","affiliation":[{"name":"Genomic Health Initiative, Endeavor Health, Evanston, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wei","sequence":"additional","affiliation":[{"name":"Program for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Tran","sequence":"additional","affiliation":[{"name":"Program for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Ashworth","sequence":"additional","affiliation":[{"name":"Program for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqun Lilly","family":"Zheng","sequence":"additional","affiliation":[{"name":"Program for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Lu","sequence":"additional","affiliation":[{"name":"GoPath Diagnostics, Buffalo Grove, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R","family":"Sanders","sequence":"additional","affiliation":[{"name":"Genomic Health Initiative, Endeavor Health, Evanston, Illinois, USA"},{"name":"The University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Helfand","sequence":"additional","affiliation":[{"name":"The University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA"},{"name":"Division of Urology, Endeavor Health, Evanston, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-8752","authenticated-orcid":false,"given":"Jianfeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Program for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA"},{"name":"The University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2026092903151198000_63.10.676.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228"},{"key":"2026092903151198000_63.10.676.2","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026092903151198000_63.10.676.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503223"},{"key":"2026092903151198000_63.10.676.4","first-page":"29801017","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement","volume":"319","author":"Force","year":"2018","journal-title":"JAMA"},{"key":"2026092903151198000_63.10.676.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3712"},{"key":"2026092903151198000_63.10.676.6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamasurg.2024.4811","article-title":"Imaging in diagnosis and active surveillance for prostate cancer: a review","volume":"160","author":"Li","year":"2025","journal-title":"JAMA Surg"},{"key":"2026092903151198000_63.10.676.7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0060"},{"key":"2026092903151198000_63.10.676.8","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003491"},{"key":"2026092903151198000_63.10.676.9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37657","article-title":"Benefit, harm, and cost-effectiveness associated with magnetic resonance imaging before biopsy in age-based and risk-stratified screening for prostate cancer","volume":"4","author":"Callender","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026092903151198000_63.10.676.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.17703"},{"key":"2026092903151198000_63.10.676.11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae Insights: Prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2026092903151198000_63.10.676.12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0007"},{"key":"2026092903151198000_63.10.676.13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/pros.24918","article-title":"Germline testing for prostate cancer patients: evidence-based evaluation of genes recommended by NCCN guidelines","volume":"85","author":"Xu","year":"2025","journal-title":"Prostate"},{"key":"2026092903151198000_63.10.676.14","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","article-title":"Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer","volume":"9","author":"Darst","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026092903151198000_63.10.676.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-56944-1","article-title":"Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases","volume":"16","author":"Mitchell","year":"2025","journal-title":"Nat Commun"},{"key":"2026092903151198000_63.10.676.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa075819"},{"key":"2026092903151198000_63.10.676.17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2020.11.014","article-title":"Performance of three inherited risk measures for predicting prostate cancer incidence and mortality: a population-based prospective analysis","volume":"79","author":"Shi","year":"2021","journal-title":"Eur Urol"},{"key":"2026092903151198000_63.10.676.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00748-0"},{"key":"2026092903151198000_63.10.676.19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.euros.2022.09.001","article-title":"Reliability of ancestry-specific prostate cancer genetic risk score in four racial and ethnic populations","volume":"45","author":"Shi","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"2026092903151198000_63.10.676.20","first-page":"39974097","article-title":"Specificity of a polygenic score for aggressive prostate cancer","volume":"25","author":"Dornisch","year":"2025","journal-title":"medRxiv"},{"key":"2026092903151198000_63.10.676.21","doi-asserted-by":"crossref","first-page":"38366150","DOI":"10.1093\/jncics\/pkae008","article-title":"Using clinical and genetic risk factors for risk prediction of 8 cancers in the UK Biobank","volume":"8","author":"Hu","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"2026092903151198000_63.10.676.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2023.05.010"},{"key":"2026092903151198000_63.10.676.23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.eururo.2025.09.4161","article-title":"Integrating pathogenic variants, polygenic risk score, and family history for prostate cancer risk estimation in men of African ancestry","volume":"89","author":"Chen","year":"2026","journal-title":"Eur Urol"},{"key":"2026092903151198000_63.10.676.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407934"},{"key":"2026092903151198000_63.10.676.25","doi-asserted-by":"crossref","first-page":"101659","DOI":"10.1016\/j.gim.2025.101659","article-title":"Consideration of inherited cancer risk on a continuum: an international and multidisciplinary perspective: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"28","author":"Pal","year":"2026","journal-title":"Genet Med"},{"key":"2026092903151198000_63.10.676.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0579-z"},{"key":"2026092903151198000_63.10.676.27","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00081","article-title":"Polygenic score complements family history and Lynch syndrome genes for predicting colorectal cancer risk","volume":"9","author":"Helfand","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"2026092903151198000_63.10.676.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2017.01.004"},{"key":"2026092903151198000_63.10.676.29","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"2026092903151198000_63.10.676.30","unstructured":"ClinGen . Sequence variant interpretation. n.d. Available: https:\/\/clinicalgenome.org\/working-groups\/sequence-variant-interpretation\/"},{"key":"2026092903151198000_63.10.676.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00783-5"},{"key":"2026092903151198000_63.10.676.32","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.035658"},{"key":"2026092903151198000_63.10.676.33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bju.15968","article-title":"Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk","volume":"131","author":"Cussenot","year":"2023","journal-title":"BJU Int"},{"key":"2026092903151198000_63.10.676.34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djae002","article-title":"Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry","volume":"116","author":"Lee","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026092903151198000_63.10.676.35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041343","article-title":"The combined effect of polygenic risk score and prostate health index in Chinese men undergoing prostate biopsy","volume":"12","author":"Ruan","year":"2023","journal-title":"J Clin Med"},{"key":"2026092903151198000_63.10.676.36","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac199"},{"key":"2026092903151198000_63.10.676.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00458-6"},{"key":"2026092903151198000_63.10.676.38","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20970"},{"key":"2026092903151198000_63.10.676.39","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78304","article-title":"Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: a meta-analysis within diverse populations","volume":"11","author":"Chen","year":"2022","journal-title":"Elife"},{"key":"2026092903151198000_63.10.676.40","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-022-00266-8","article-title":"Prostate cancer polygenic risk score and prediction of lethal prostate cancer","volume":"6","author":"Klein","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026092903151198000_63.10.676.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21287-0","article-title":"Polygenic hazard score is associated with prostate cancer in multi-ethnic populations","volume":"12","author":"Huynh-Le","year":"2021","journal-title":"Nat Commun"},{"key":"2026092903151198000_63.10.676.42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.euf.2025.02.007","article-title":"Discovery of a recurrent frameshift Ashkenazi Jewish founder mutation (F722fs) in the PARP inhibitor-sensitive MMS22L gene associated with higher risk of prostate cancer","volume":"11","author":"Isaacs","year":"2025","journal-title":"Eur Urol Focus"},{"key":"2026092903151198000_63.10.676.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01966-6"},{"key":"2026092903151198000_63.10.676.44","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/pros.70037","article-title":"Confirmation of BIK and SAMHD1 as prostate cancer susceptibility genes","volume":"85","author":"Pavlovich","year":"2025","journal-title":"Prostate"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2026-111746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:15:51Z","timestamp":1790676951000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2026-111746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,29]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/jmg-2026-111746"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2026-111746","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}